Compare TG Therapeutics Inc (TGTX) vs Vanguard Total World Stock Index Fund ETF (VT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Vanguard Total World Stock Index Fund ETF — how do they compare? TG Therapeutics Inc trades at $55.37 (market cap $8.16B), while Vanguard Total World Stock Index Fund ETF trades at $159.83 (market cap $101.70B). The key difference: Vanguard Total World Stock Index Fund ETF is far larger — about 12.5× TG Therapeutics Inc's market cap, and Vanguard Total World Stock Index Fund ETF is more actively traded (1,783,794 versus 1,735,121). Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and Vanguard Total World Stock Index Fund ETF for 53 Days on average.
| TGTX | VT | |
|---|---|---|
Market Cap | $8.16B | $101.70B |
Volume | 1,735,121 | 1,783,794 |
Sector | Health | Broad Market / Factor |
52-Week High | $59.06 | $162.39 |
52-Week Low | $26.94 | $134.19 |
Typical Hold Time | 16 Days | 53 Days |
Enterprise Value | $8.37B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $53.34, up 0.74% today, but faces bearish technical signals despite strong profitability metrics like a 55.22% net income margin. Recent earnings misses and a shareholder investigation create headwinds, though revenue growth and a high analyst buy consensus of 84.62% suggest underlying strength. The stock's current price is near key support at $52, with resistance at $54.
The outlook is mixed: robust revenue growth and institutional buying support upside toward the $80.50 consensus target, but earnings misses and legal risks pose challenges. Investors should weigh the company's MS therapy momentum against execution and regulatory uncertainties for balanced risk-reward assessment.
VT trades at $158.73, down 0.57% on the day, with technical indicators showing a bearish bias as moving averages signal selling pressure. The ETF maintains its position as a comprehensive global equity vehicle with over 9,700 holdings and a 0.06% expense ratio. Recent news highlights VT's diversification benefits and cost competitiveness against peers like Schwab International Equity ETF and iShares MSCI World ETF.
The outlook remains favorable for long-term investors seeking broad global exposure, though near-term technical weakness suggests potential testing of support levels. Key risks include global market volatility and currency fluctuations, while institutional activity shows mixed positioning with recent sales by Barry Investment Advisors offset by new stakes from FAS Wealth Partners.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Vanguard Total World Stock Index Fund ETF
VT is a foundational, low-cost ETF that seeks to track the FTSE Global All Cap Index, providing exposure to nearly 10,000 stocks across developed and emerging markets worldwide, including the United States. It serves as a single-ticker solution for total global equity diversification, capturing approximately 98% of the world's investable market capitalization.
Read more on VT →
